Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Treating cancer is a massive business. In 2024 alone, cancer treatments generated at least $200 billion in worldwide sales for the pharmaceutical industry, more than the obesity drug rush. But a Bloomberg News analysis showed that fewer than half of treatments reviewed — some of which have painful side effects — have been shown to extend patients’ lives.
On today’s Big Take podcast, Bloomberg senior healthcare reporter Robert Langreth takes host David Gura inside what some doctors call the “cancer-industrial complex” — from the regulatory landscape that ushered in a wave of lucrative new drugs to the damaging financial and health impacts some treatments can have on patients.
Read more:
Cancer Drugs Cost More Than Ever. They Often Don’t Extend Lives.
The Implants Were Supposed to Dissolve. They Didn’t.
Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work
Cancer Doctors Are Making a Fortune Off Drug-Trial Participants
One Generic Cancer Drug Costs $35. Or $134. Or $13,000.
See omnystudio.com/listener for privacy information.